These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 27475741

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal.
    Cerva C, Maffongelli G, Svicher V, Salpini R, Colagrossi L, Battisti A, Mariotti B, Cerretti R, Cudillo L, Sarmati L.
    BMC Infect Dis; 2017 Aug 15; 17(1):566. PubMed ID: 28806922
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor.
    Knöll A, Boehm S, Hahn J, Holler E, Jilg W.
    J Viral Hepat; 2007 Jul 15; 14(7):478-83. PubMed ID: 17576389
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Reactivation of hepatitis B virus in hematopoietic stem cell transplant recipients in Japan: efficacy of nucleos(t)ide analogues for prevention and treatment.
    Nakamoto S, Kanda T, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, Takeda Y, Mimura N, Iseki T, Wu S, Arai M, Imazeki F, Saito K, Shirasawa H, Yokosuka O.
    Int J Mol Sci; 2014 Nov 21; 15(11):21455-67. PubMed ID: 25421241
    [Abstract] [Full Text] [Related]

  • 10. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center.
    Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC.
    Transpl Infect Dis; 2020 Apr 21; 22(2):e13243. PubMed ID: 31901206
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
    Sarmati L, Andreoni M, Antonelli G, Arcese W, Bruno R, Coppola N, Gaeta GB, Galli M, Girmenia C, Mikulska M, Pane F, Perno CF, Picardi M, Puoti M, Rambaldi A, Svicher V, Taliani G, Gentile G.
    Clin Microbiol Infect; 2017 Dec 21; 23(12):935-940. PubMed ID: 28668466
    [Abstract] [Full Text] [Related]

  • 13. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.
    Shang J, Wang H, Sun J, Fan Z, Huang F, Zhang Y, Jiang Q, Dai M, Xu N, Lin R, Liu Q.
    Bone Marrow Transplant; 2016 Apr 21; 51(4):581-6. PubMed ID: 26752138
    [Abstract] [Full Text] [Related]

  • 14. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.
    Hsiao LT, Chiou TJ, Liu JH, Chu CJ, Lin YC, Chao TC, Wang WS, Yen CC, Yang MH, Tzeng CH, Chen PM.
    Biol Blood Marrow Transplant; 2006 Jan 21; 12(1):84-94. PubMed ID: 16399572
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation.
    Wu Y, Huang H, Luo Y.
    Front Immunol; 2020 Jan 21; 11():610500. PubMed ID: 33613534
    [Abstract] [Full Text] [Related]

  • 18. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: risk factors and outcome.
    Mikulska M, Nicolini L, Signori A, Rivoli G, Del Bono V, Raiola AM, Di Grazia C, Dominietto A, Varaldo R, Ghiso A, Bacigalupo A, Viscoli C.
    Clin Microbiol Infect; 2014 Oct 21; 20(10):O694-701. PubMed ID: 24575948
    [Abstract] [Full Text] [Related]

  • 19. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.
    Viganò M, Vener C, Lampertico P, Annaloro C, Pichoud C, Zoulim F, Facchetti F, Poli F, Scalamogna M, Deliliers GL, Colombo M.
    Bone Marrow Transplant; 2011 Jan 21; 46(1):125-31. PubMed ID: 20383209
    [Abstract] [Full Text] [Related]

  • 20. [A clinical study of allo-hematopoietic stem cell transplantation in HBsAg positive leukemia].
    Chen Y, Xu LP, Liu KY, Liu DH, Han W, Chen H, Zhang YC, Chen YH, Huang XJ.
    Zhonghua Nei Ke Za Zhi; 2008 Apr 21; 47(4):316-9. PubMed ID: 18843958
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.